Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CALML3 | P27482 | 1/20 | 0.54 |
| ▸ | SDHA | P31040 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102671 | 0.90 | F10 (0.70) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL92950 | 0.85 | F10 (0.71) | F10MAOBMAOA | |
| SCHEMBL78885 | 0.83 | F10 (0.83) | F10 | |
| SCHEMBL5220160 | 0.83 | MAOB (0.65) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5221998 | 0.82 | MAOA (0.78) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6058550 | 0.82 | MAOA (0.78) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL14477113 | 0.82 | F10 (0.56) | F10MAOBMAOA | |
| SCHEMBL14641457 | 0.82 | F10 (0.67) | F10MAOBMAOA | |
| SCHEMBL13103180 | 0.82 | F10 (0.67) | F10MAOBMAOA | |
| SCHEMBL18410477 | 0.81 | MAOB (0.78) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | OTC, SDHA, SDHB | F10 258/4885MAOB 81/4885MAOA 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.